Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

QA102 fase II-studie i forsøgspersoner med tør AMD (AMEND)

8. september 2026 opdateret af: Smilebiotek Zhuhai Limited

En fase 2, dobbeltmaskeret, randomiseret, placebokontrolleret, dosis-respons undersøgelse, der vurderer sikkerheden og effektiviteten af ​​QA102 hos forsøgspersoner med tør aldersrelateret makuladegeneration (AMD)

This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

150

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85021
        • Associated Retina Consultants
    • California
      • Mountain View, California, Forenede Stater, 94040
        • Northern California Retina Vitreous Associates Medical Group
      • Pasadena, California, Forenede Stater, 91107
        • California Eye Specialists Medical Group
      • Redlands, California, Forenede Stater, 91107
        • California Eye Specialists Medical Group
    • Colorado
      • Colorado Springs, Colorado, Forenede Stater, 80909
        • Retina Consultants of Southern Colorado, P.C.
    • Florida
      • Deerfield Beach, Florida, Forenede Stater, 33064
        • Advanced Research
      • Fort Myers, Florida, Forenede Stater, 33912
        • National Ophthalmic Research Institute
      • Miami, Florida, Forenede Stater, 33143
        • MedEye Associates
      • Pensacola, Florida, Forenede Stater, 32503
        • Retina Specialty Institute
      • Pinellas Park, Florida, Forenede Stater, 33782
        • Eye Associates of Pinellas
      • Sarasota, Florida, Forenede Stater, 34239
        • Sarasota Retina Institute
      • Winter Haven, Florida, Forenede Stater, 33880
        • Vitreous and Retina Consultants
    • Georgia
      • Marietta, Georgia, Forenede Stater, 30060
        • Marietta Eye Clinic
    • Illinois
      • Oak Forest, Illinois, Forenede Stater, 60452
        • University Retina and Macula Associates
    • Louisiana
      • West Monroe, Louisiana, Forenede Stater, 71291
        • Northeast Louisiana dba Haik Humble Eye Center
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21209
        • The Retina Care Center
      • Hagerstown, Maryland, Forenede Stater, 21740
        • Cumberland Valley Retina Consultants
      • Hagerstown, Maryland, Forenede Stater, 21740
        • Mid Atlantic Retina Specialists
    • Massachusetts
      • Worcester, Massachusetts, Forenede Stater, 01605
        • Vitreo-Retinal Associates, P.C.
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63144
        • Retina Research Institute
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45202
        • Velocity Clinical Research
    • Oregon
      • Eugene, Oregon, Forenede Stater, 97401
        • Verum Research, LLC
    • Pennsylvania
      • Erie, Pennsylvania, Forenede Stater, 16507
        • Erie Retina Research
    • Texas
      • Abilene, Texas, Forenede Stater, 79606
        • Retina Research Institute of Texas
      • Austin, Texas, Forenede Stater, 78705
        • Austin Research Center for Retina
      • Dallas, Texas, Forenede Stater, 75243
        • AXIS Clinicals LLC / Retina of North Texas
      • Plano, Texas, Forenede Stater, 75075
        • Texas Retina Associates - Plano
      • San Antonio, Texas, Forenede Stater, 78215
        • San Antonio Eye Center
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84107
        • Rocky Mountain Retina Consultants

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

50 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  • Subject must be able to understand and willing to sign a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
  • Subject must be age ≥50 years at the time of informed consent.
  • Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
  • Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
  • Subject must be willing and able to comply with study procedures and examinations.

Specific to the Study Eye:

  • Subject must have one of the following:

    • extensive intermediate-size drusen, or at least 1 large drusen, or
    • GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
  • Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).

Specific to Fellow Eye:

- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.

Specific to Both Eyes:

- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.

Key Exclusion Criteria:

  • Subject received an active investigational drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
  • Subject has ever received gene therapy (for any condition).
  • Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
  • Subject has a clinically significant systemic disease that might interfere with the study, in the judgment of the Investigator.
  • Subject had major surgery within 30 days prior to Screening.

Specific to Study Eye:

  • Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
  • Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
  • Subject has endophthalmitis.
  • Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
  • Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
  • Subject has aphakia or absence of the posterior capsule.
  • Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)

Specific to Fellow Eye:

Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.

Specific to Either Eye:

  • Subject had intraocular surgery with lens replacement within 3 months of Screening.
  • Subject has any ophthalmic condition that could require surgery during the study period.
  • Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: QA102 200mg group

Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months

Capsules

Eksperimentel: QA102 400mg group

Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months

Capsules

Placebo komparator: Placebo group

Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months

Capsules

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change From Baseline in Soft Drusen Volume (mm3)
Tidsramme: Month 12

Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set

Month 12

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean Rate of GA Growth
Tidsramme: Month 12

Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline

Month 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. september 2022

Primær færdiggørelse (Faktiske)

12. november 2024

Studieafslutning (Faktiske)

12. november 2024

Datoer for studieregistrering

Først indsendt

8. september 2022

Først indsendt, der opfyldte QC-kriterier

8. september 2022

Først opslået (Faktiske)

13. september 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

1. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

8. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • QA102-CS201

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .